NCT04858919

Brief Summary

This study is to compare the feasibility and test performance of different 3D pelvic ultrasound and Transrectal ultrasound in the detection of local lesions in the uterus , cervix and vagina compared to the final diagnosis confirmed by vaginoscopy as a golden standard modality of diagnosis in Virgin Patients

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jun 2019

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2019

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2021

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2021

Completed
12 days until next milestone

First Submitted

Initial submission to the registry

April 13, 2021

Completed
13 days until next milestone

First Posted

Study publicly available on registry

April 26, 2021

Completed
Last Updated

April 26, 2021

Status Verified

April 1, 2021

Enrollment Period

1.8 years

First QC Date

April 13, 2021

Last Update Submit

April 21, 2021

Conditions

Outcome Measures

Primary Outcomes (2)

  • Feasibility of different diagnostic modalities in Virgins.

    By questionnaire to asses the acceptance of patient to undergo different modalities as 3D pelvic ultrasound, Transrectal ultrasound and vaginoscopy is assessed.

    1 to 2 hours

  • Test performance of different diagnostic modalities in Virgins

    diagnostic accuracy of 3D pelvic ultrasound and Transrectal ultrasound in the detection of local lesions in the uterus, cervix and vagina compared to the final diagnosis confirmed by vaginoscopy as a golden standard modality of diagnosis in Virgins.

    24 hours to 1 week

Secondary Outcomes (2)

  • Patients' satisfaction

    1-2 hours

  • patients' pain

    1-2 hours

Study Arms (1)

study group

OTHER

virgins with genital tract lesion

Diagnostic Test: 3D transabdominal ultrasoundDiagnostic Test: transrectal ultrasoundDiagnostic Test: vaginoscopy

Interventions

Initially 3D pelvic ultrasound will be performed on all patients. The transabdominal probes used will be those of the ultrasound scanner using a convex probe (multiple frequency 1-6 MHz).

study group
transrectal ultrasoundDIAGNOSTIC_TEST

The vaginal probe will be covered with the customary plastic sheath and richly lubricated with lubricating gel. The probe will then be slowly advanced into the rectum. The transvaginal probes used will be those of the ultrasound scanner using a vaginal probe (multiple frequency 1-8 MHz). The scanning technique will be similar to that of Transvaginal ultrasound.

study group
vaginoscopyDIAGNOSTIC_TEST

It is the final procedure in the study to reach the accurate diagnosis. A rigid hysteroscope will be used. The sheath has a 5-mm outer diameter, with 2.9 mm rod lens. A high intensity light source and fiberoptic cable will be used to illuminate the uterine cavity. A solution of 0.9% normal saline will be used as the distention medium. The pressure will be kept at 100-120 mmHg using a pressure adjustable cuff system with the aim of maintaining the lowest pressure required to distend the uterine cavity.

study group

Eligibility Criteria

Age5 Years - 55 Years
Sexfemale
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Virgins complaining of Abnormal vaginal bleeding, abnormal discharge , pelvic pain
  • Virgins with Suspected genital tract lesion by examination
  • Virgins with Suspected genital tract lesion by pelvic ultrasound

You may not qualify if:

  • Sexually Active Patients
  • Suspected or documented Pregnancy
  • Virgin patients with no suspected uterine, cervical or vaginal lesion by pelvic ultrasound
  • Patients unable to communicate effectively

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ain shams university faculty of medicine

Cairo, 11591, Egypt

Location

MeSH Terms

Conditions

Sexual AbstinenceGenital Diseases, Female

Condition Hierarchy (Ancestors)

Sexual BehaviorBehaviorFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Masking Details
The sonographers will be blinded to all images obtained from the initial pelvic ultrasound and from the images obtained by the alternative sonographic modality. Also All sonographic images will be concealed from the physicians performing the vaginoscopy procedure .
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Model Details: A diagnostic test accuracy study that will be conducted at Ain-Shams University Maternity Hospital ,the patients will be recruited from women admitted from gynecologic clinic or from emergency room and from patients following up in outpatient clinic patients will be recruited to this study All Patients recruited must have suspected uterine, cervical or vaginal lesion by history, examination and Pelvic ultrasound
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 13, 2021

First Posted

April 26, 2021

Study Start

June 1, 2019

Primary Completion

March 1, 2021

Study Completion

April 1, 2021

Last Updated

April 26, 2021

Record last verified: 2021-04

Data Sharing

IPD Sharing
Will share
Shared Documents
STUDY PROTOCOL, SAP, ICF, ANALYTIC CODE
Time Frame
6 months after publishing

Locations